Highland Capital Management (Texas)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Highland Capital Management (Texas)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$514K	Buy	6,000 +3,000	+100%	+$257K	0.03%	251
2019 Q1	$266K	Sell	3,000 -1,500	-33%	-$139K	0.02%	282
2018 Q4	$383K	Buy	4,500 +2,050	+84%	+$195K	0.03%	214
2018 Q3	$238K	Hold	2,450	–	–	0.01%	290
2018 Q2	$231K	Sell	2,450 -13,960	-85%	-$1.22M	0.01%	301
2018 Q1	$1.33M	Buy	16,410 +13,960	+570%	+$1.2M	0.07%	171
2017 Q4	$218K	Hold	2,450	–	–	0.01%	285
2017 Q3	$228K	Hold	2,450	–	–	0.01%	277
2017 Q2	$223K	Hold	2,450	–	–	0.01%	272
2017 Q1	$215K	Sell	2,450 -17,839	-88%	-$1.59M	0.01%	274
2016 Q4	$1.68M	Buy	20,289 +17,839	+728%	+$1.53M	0.08%	149
2016 Q3	$227K	Sell	2,450 -40,000	-94%	-$3.77M	0.01%	289
2016 Q2	$3.3M	Sell	42,450 -73,521	-63%	-$6.25M	0.14%	138
2016 Q1	$9.56M	Buy	+115,971	New	+$9.44M	0.42%	64

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Highland Capital Management (Texas)'s BMRN Position: Q2 2019 in Review

Highland Capital Management (Texas) increased its BioMarin Pharmaceuticals (BMRN) stake by 100% in Q2 2019, buying an estimated $257K and bringing the position to 6,000 shares worth $514K. The position accounts for 0.03% of the portfolio, ranked #251.

Highland Capital Management (Texas) first reported a position in BMRN in Q1 2016 and has held it in 14 quarters since. The position peaked at $9.56M in Q1 2016. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Highland Capital Management (Texas) held 6,000 shares of BioMarin Pharmaceuticals worth $514K as of Q2 2019.
Highland Capital Management (Texas) bought 3,000 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $257K.
BioMarin Pharmaceuticals made up 0.03% of Highland Capital Management (Texas)'s portfolio in Q2 2019, its #251 holding.
Highland Capital Management (Texas) first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 14 quarters since.
Highland Capital Management (Texas)'s BioMarin Pharmaceuticals position peaked at $9.56M in Q1 2016.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Highland Capital Management (Texas)'s 13F filing for Q2 2019, filed 14 Aug 2019.